Deducing Mucosal Pharmacokinetics and Pharmacodynamics of the Anti-HIV Molecule Tenofovir from Measurements in Blood
Authors:
Open Access
- 14 January 2019
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 9 (1) , 82
Abstract
Microbicide pharmacokinetic (PK) studies typically sample drug in luminal fluid, mucosal tissue, and blood. Blood measurements can be conducted most frequently, serially within subjects. Antiretroviral drugs, however, act against HIV in mucosal tissue/cells. We computationally modeled the extent measurements in blood can predict concentrations in tissue, focusing on the antiretroviral drug tenofovir delivered by a vaginal gel. Deterministic PK models input host and product factors and output spatiotemporal drug concentrations in luminal fluid, epithelium, stroma/host cells, and blood. Pharmacodynamic (PD) analysis referenced stroma/host cell concentrations to prophylactic values; summary metrics were time from product insertion to protection (tlag) and degree of protection (PPmax). Results incorporated host factors characteristic of population variability. Neural nets (NN) linked simulated blood PK metrics (Cmax, tmax, AUC, C24) to mucosal PK/PD metrics. The NNs delivered high-performance mapping of these multiparametric relationships. Given multi-log variability typical of biopsy data for tenofovir and other topical microbicides, results suggest downstream but higher fidelity measurements in blood could help improve determination of PK and create inferences about PD. Analysis here is for a tenofovir gel, but this approach offers promise for application to other microbicide modalities and to topical drug delivery to vaginal mucosa more generally.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (AI 13127)
This publication has 51 references indexed in Scilit:
- White Paper: Landscape on Technical and Conceptual Requirements and Competence Framework in Drug/Disease Modeling and SimulationCPT: Pharmacometrics & Systems Pharmacology, 2013
- A Phase 1 Randomized, Double Blind, Placebo Controlled Rectal Safety and Acceptability Study of Tenofovir 1% Gel (MTN-007)PLOS ONE, 2013
- MTN-001: Randomized Pharmacokinetic Cross-Over Study Comparing Tenofovir Vaginal Gel and Oral Tablets in Vaginal Tissue and Other CompartmentsPLOS ONE, 2013
- Drug-Eluting Fibers for HIV-1 Inhibition and ContraceptionPLOS ONE, 2012
- A Multi-Compartment, Single and Multiple Dose Pharmacokinetic Study of the Vaginal Candidate Microbicide 1% Tenofovir GelPLOS ONE, 2011
- Microbicides: Topical Prevention against HIVCold Spring Harbor Perspectives in Medicine, 2011
- Effectiveness and Safety of Tenofovir Gel, an Antiretroviral Microbicide, for the Prevention of HIV Infection in WomenScience, 2010
- Compartmental Transport Model of Microbicide Delivery by an Intravaginal RingJournal of Pharmaceutical Sciences, 2010
- Advances in the Development of Microbicides for the Prevention of HIV InfectionCurrent Infectious Disease Reports, 2010
- Development of topical microbicides to prevent the sexual transmission of HIVAntiviral Research, 2010